Managing type 2 diabetes and obesity has been revolutionized by medications like dulaglutide, semaglutide, and tirzepatide, but here’s the catch: these life-changing treatments come with a side effect that’s hard to ignore—gastrointestinal issues. A recent cohort study has shed light on this, revealing that all three medications carry a comparable risk of gastrointestinal adverse events (AEs), such as nausea, vomiting, and constipation. But here’s where it gets controversial: while these drugs are equally likely to cause stomach troubles, they’re still preferred over sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in many cases. Why? Because their benefits often outweigh the risks—but at what cost to patients’ comfort?
In this study, researchers compared the gastrointestinal AEs of dulaglutide, semaglutide, and tirzepatide in adults with type 2 diabetes (T2DM). They found that whether it was dulaglutide versus semaglutide, tirzepatide versus dulaglutide, or tirzepatide versus semaglutide, the risk of gastrointestinal issues remained strikingly similar. And this is the part most people miss: even in patients using insulin or opioids—groups already at higher risk for AEs—the results held steady.
The study included over 300,000 patients, divided into three cohorts based on the medications they were taking. Researchers tracked severe gastrointestinal events like pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation. Despite slight differences in patient demographics—like age—the outcomes were consistent: no single medication stood out as safer or riskier than the others.
But here’s the twist: when compared to SGLT-2 inhibitors, all three medications showed a higher risk of gastrointestinal AEs, particularly those related to motility issues like constipation or obstruction. This raises a thought-provoking question: Are we sacrificing digestive health for better blood sugar control?
The study isn’t without its limitations. There’s a chance some AEs were misclassified or underreported, and the researchers couldn’t account for specific doses of the medications. Still, the findings are clear: in real-world settings, dulaglutide, semaglutide, and tirzepatide are neck-and-neck when it comes to gastrointestinal risks.
So, what does this mean for you? If you’re a clinician, this study gives you solid evidence to weigh the benefits and risks when prescribing these medications. And if you’re a patient, it’s a reminder to have open conversations with your doctor about potential side effects.
But let’s end with a question for you: Do you think the gastrointestinal risks of these medications are worth the benefits they provide? Or should we be pushing for safer alternatives? Let us know in the comments—we’d love to hear your thoughts!
